Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2020

View Archived Issues

ADAM9 expression correlates with poor survival in TNBC

Discovery of novel BET protein degraders as oncolytic drug candidates

Crosstalk between sex, stress hormones affects immunity

Astrocytes, endocannabinoids, metabolism cooperate to affect behavior

Liver-specific silencing of MCJ reduces steatosis, inflammation and fibrosis in NASH mouse models

Roche synthesizes new imidazopyrazine antibacterials

Humanwell Healthcare, Hubei Bio-Pharmaceutical patent PDE4 inhibitors

Phase II study of CS-02 meets primary endpoint

New SMARCA2 inhibitors identified at Bayer

Imperial Innovations Group presents N-myristoyltransferase inhibitors

Svenox Pharmaceuticals presents new antitubercular compounds

Aptahem and University Health Network collaborate to develop Apta-1 for treatment of COVID-19

First-in-human study of INV-1120

Aligos Therapeutics presents preclinical data on ALG-031048

NBE-Therapeutics initiates phase I/II study of NBE-002

Enrollment ongoing in phase I study of KBL-693

Celldex Therapeutics starts enrollment in phase I study of CDX-527

BRAF inhibitor ABM-1310 displays potent efficacy in xenograft cancer models

Oragenics advances TerraCoV2, ends development of AG-013 for oral mucositis

Alzumab approved in India for emergency use to treat CRS in patients with COVID-19-related ARDS

Australia's TGA grants provisional approval to remdesivir

Beta Pharma begins phase I/II study of BPI-1178 in advanced solid tumors and breast cancer

Mutation drives checkpoint resistance in gastric cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...